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Abstract  The  stated  aims  of  treating  acute  deep  vein  thrombosis  (DVT)  are  to  prevent  a  pul-
monary embolism,  stop  the  clot  from  spreading,  reduce  the  risk  of  a  recurrence;  they  are  less
concerned  with  the  late  morbidity  associated  with  post-thrombotic  syndrome  (PTS).  In  accor-
dance with  the  French  (Afssaps,  2009)  and  North  American  (ACCP,  2008)  recommendations,
anticoagulants  (LMWH,  heparin,  AVK)  form  the  cornerstone  for  treating  DVT.  These  treatments
appear to  be  far  less  effective  in  preventing  post-thrombotic  syndrome  (PTS),  associated  with
venous hypertension,  residual  occlusion,  and  with  reﬂux  caused  by  valve  incompetence.  Given
that, the  new  aim  is  to  optimise  the  prevention  of  PTS,  the  ACCP  guidelines,  unlike  those  of
Afssaps, ‘‘suggest’’  for  selected  patients  suffering  from  acute  iliofemoral  DVT,  the  use  of  both
classic anticoagulants,  and  in  situ  percutaneous  administration  of  thrombolytic  drugs  (recom-
mendation grade  2B)  and  simultaneous  correction  of  any  underlying  anatomical  anomalies  using
angioplasty  and  stenting  (recommendation  2C).  Contemporary  endovascular  methods,  referred
to collectively  as  ‘‘facilitated’’  thrombolysis,  combine  low  doses  of  rtPa  or  Urokinase  adminis-
tered locally,  and  the  removal  of  the  clot  using  various  mechanical,  rotating,  rheolytic  systems,
or using  ultrasound.  The  results  of  non-randomised,  heterogeneous  studies  objectivised  a  lysis
rate of  80%,  a  50%  lower  risk  of  haemorrhage  complications  compared  with  systemic  thrombo-
lysis (<  4%),  and  a  clear  reduction  in  treatment  time  (one-shot  methods  possible  for  procedures
lasting less  than  2  hours).  This  data  ties  in  with  the  modern  ‘‘open  vein’’  concept  which  under-
pins the  hope  of  an  improvement  in  the  late  prognosis  of  acute  DVT,  through  the  removal  of
a clot,  thereby  improving  permeability  and  valve  integrity;  this  hypothesis  is  supported  by  the
results at  24  months  of  a  randomised  CaVent  objectifying  absolute  risk  reduction  of  15%  in  the
thrombolysis  in  situ.  The  current  randomised  study  (ATTRACT  trial)  comparing  the  combination
of ‘‘facilitated  thrombolysis’’  in  addition  to  the  usual  treatment  with  the  traditional  treatment
alone for  acute  iliofemoral  DVT,  the  statistical  power  of  which  has  been  established  (600
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patients)  to  authenticate  a  reduction  by  a  third  in  the  number  of  PTS  (CaVent  trial,  showing
a 15%  reduction  rate  of  24  months  PTS  in  the  thrombolysed  group  results  expected  in  2016),
might, if  the  results  are  positive,  lead  to  a  profound  change  in  the  paradigms  for  the  treatment
of acute  iliofemoral  DVT.
©  2012  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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everview of the situation
n  France,  the  recommendations  for  good  practice  that  gov-
rn  the  prevention  and  treatment  of  venous  thromboembolic
isease  in  medical  practice,  drawn  up  in  2009  by  the  working
roup  of  the  French  Health  Products  Safety  Agency  (Afs-
aps),  stipulate  that  the  use  of  thrombolytic  drugs  is  not
ecommended  as  ﬁrst-line  treatment  during  the  acute  phase
grade  B  in  the  classiﬁcation  chosen  by  the  French  National
ealth  Evaluation  and  Accreditation  Agency  (ANAES)  and  the
rench  National  Health  Authority  (HAS)  or  ‘‘scientiﬁc  pre-
umption’’)  [1].  The  arguments  behind  this  negative  position
aken  by  the  group  of  experts  are  based  purely  on  the  conclu-
ions  of  a  meta-analysis  of  randomised  trials  that  assessed
he  effect  of  the  systemic  injection  of  thrombolytic  drugs
versus  usual  antithrombotic  treatment),  published  in  2004
y  the  Cochrane  Agency  [2].  This  meta-analysis  included  11
rials  and  700  patients,  the  vast  majority  of  whom  were
reated  with  high  doses  of  Streptokinase  or  Urokinase.  The
nalysis  concluded  that  the  scale  of  the  adverse  effects,
ainly  serious  haemorrhaging  complications  (10%,  with  an
ncrease  in  the  relative  risk  of  73%),  considerably  out-
eighed  the  beneﬁts  observed  (an  increase  in  the  relative
isk  of  full  lysis  of  the  clot  by  76%,  and  a  reduction  in  the
elative  risk  of  a  post-thrombotic  syndrome  of  33%)  (Fig.  1).
The  report  by  Afssaps  was  also  of  the  opinion  that
iven  the  current  level  of  knowledge,  there  is  no  data
vailable  to  suggest  that  one  route  of  administration  is
etter  than  another  (local  in  situ,  or  systemic).  It  did  how-
ver  state  that  if  a  group  of  medical  and  surgical  experts
ork  together,  thrombolytic  drugs  could  be  administered
ia  the  systemic  venous  route  if  the  patient  suffers  a  seri-
us  obstructive  syndrome  or  phlegmatia  caerulea  dolens  in
rder  to  prevent  the  condition  turning  into  gangrene,  or
equiring  amputation  (grade  C).  These  recommendations  on
he  precise  issues  of  indication  and  the  route  of  admin-
stration  for  thrombolytic  drugs  are  different  from  those
aid  down  by  the  American  College  of  Chest  Physicians  [3].
he  recommendations  are  based  not  only  on  the  Cochrane
eta-analysis  carried  out  in  2004,  but  also  on  the  assess-
ent  of  exhaustive  documentation,  prior  to  and  after  this
ate,  from  19  trials  [4—22], which  were  very  heteroge-
eous  (945  patients).  These  trials  were  not  randomised  but
ocussed  on  the  use  of  modern  local  in  situ  ﬁbrinolytic
rugs  at  low  doses  (rtPa,  Urokinase),  which  were  combined
ith  mechanical  procedures  to  extract  the  clot  in  the  most
ecent  cases.  This  method  revealed  a  lysis  rate  of  80%,
ith  a  reduction  in  haemorrhaging  complications  of  50%
ompared  with  the  older  studies,  and  a  considerable  fall
n  the  time  to  carry  out  the  interventional  act  (less  than
 hours  with  some  techniques).  So,  as  regards  the  treat-
ent  of  acute  deep  vein  thrombosis  (DVT),  the  authors  of
s
r
c
she  ACCP  recommendations  ‘‘suggest’’  that  for  the  patients
elected  (Fig.  2),  in  situ  thrombolysis  may  be  used  with
 view  to  reducing  the  symptoms  and  post-thrombotic
orbidity,  if  appropriate  expertise  and  resources  are  avail-
ble  (recommendation  ‘‘weak’’,  grade  2B).  After  effective
hrombolysis,  the  authors  ‘‘suggest’’  correcting  underlying
enous  morphological  anomalies,  using  balloon  angioplasty
nd  a  stent  (grade  2C).  The  same  authors  ‘‘suggest’’  that
harmacomechanical  thrombolysis  —  including  mechanical
rocedures  to  break  up/aspirate  the  clot  —  should  be  pre-
erred  to  in  situ  thrombolysis  alone,  in  order  to  reduce
reatment  time,  if  suitable  expertise  and  resources  are
vailable  (grade  2C).  Finally,  they  put  forward  the  sugges-
ion  that  if  local  thrombolysis  techniques  are  not  accessible,
ystemic  thrombolysis  may  be  considered  (grade  2C).  So,  it
an  be  seen  that  there  are  differences  of  opinion  either  side
f  the  Atlantic  with  regard  to  the  treatment  of  acute  DVT.
his  can  be  explained  mainly  by  way  of  the  different  ideas
eld  as  to  the  aims  of  the  treatment,  in  particular  regarding
he  prevention  of  late  morbidity.
ims of the treatment of acute deep vein
hrombosis
he  usual  issue  raised  by  acute  DVT,  in  clinical  practice,  is
hat  of  preventing  early  complications,  such  as  pulmonary
mbolism,  stopping  the  thrombus  spreading,  and  preven-
ing  the  recurrence  of  DVT.  The  main  choice  of  treatment
 anticoagulation  drugs  —  relatively  effectively  fulﬁls  clini-
al  objectives,  but  does  not  appear  to  be  totally  effective  in
issolving  the  thrombus,  restoring  permeability,  and  main-
aining  the  anti-reﬂux  function  of  the  valves.  Chronic  venous
nsufﬁciency  is  a  potential  late  complication  that  manifests
tself  through  the  occurrence  of  a  post-thrombotic  syn-
rome  (PTS),  with  varying  levels  of  clinical  severity,  which
s  associated  with  the  gradual  emergence  of  venous  hyper-
ension  [23]. The  clinical  consequences  are  a  change  to
ubcutaneous  tissue  and  the  skin,  through  extravasation  of
acromolecules  and  cells  [24]. The  combination  of  a  resid-
al  venous  obstruction  and  valve  incompetence  is  associated
ith  the  highest  morbidity  rate  for  PTS  [25]. The  incidence
ate  of  PTS  varies  from  20  to  50%,  2  years  after  an  acute
eep  vein  thrombosis  attack  according  to  Tick  et  al.  [26].
n  principle,  the  frequency  is  falling,  given  that  the  deﬁ-
ition  is  stricter,  based  on  the  Villalta  scale  (Fig.  3),  also
iven  that  both  its  diagnostic  and  prevention,  by  wearing  an
lastic  strap,  systematically  improved  [27]. A  natural  history
tudy  of  iliofemoral  DVT  treated  with  anticoagulants  alone
evealed  15%  of  patients  suffered  ulceration,  40%  venous
laudication,  of  which  15%  had  difﬁculty  walking,  and  100%
uffered  an  impact  on  their  quality  of  life  after  5  years,  and
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Figure 1. Randomised studies with systemic thrombolysis as reported by the Cochrane Agency 2004.
From [2].
Figure 2. Recommendations by the American College of Chest Physicians (ACCP) for the treatment of deep vein thrombosis.
From [4].
728  
Figure 3. Villalta scale and CEAP classiﬁcation of post-thrombotic
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rom [27].
ccount  for  one  of  the  major  predictive  factors  for  the  late
ccurrence  of  a  PTS,  since  the  risk  is  multiplied  by  2.6  versus
emoropopliteal  DVT  [28]. New  treatment  paradigms  have
ppeared  in  the  United  States  that  tie  in  with  the  recent
ttention  paid  to  the  harmful  consequences  of  PTS.  So  in
008,  thanks  to  SK  Galson  [29], a  ‘‘National  Call  Action  on
eep  venous  thrombosis  and  pulmonary  embolism’’  was  ini-
iated.  It  was  the  seventh  action  of  this  kind  in  11  years,  and
alled  for  resources  to  carry  out  research  into  the  causes,
revention  and  treatment  of  DVT  and  pulmonary  embolisms,
ith  priority  given  to  a  clinical  assessment  of  new  per-
utaneous  systems  for  the  thrombectomy  procedure.  It  is
ustiﬁed  in  particular  by  the  fact  that  some  current  prospec-
ive  studies  suggest  that  the  concept  of  quality  of  life  in  the
ater  stages  of  life  associated  with  DVT  needs  to  be  con-
iderably  updated,  stating  that  carrying  out  research  into
ays  of  attaining  immediate  therapeutic  objectives  alone
s  clearly  insufﬁcient  to  ensure  optimal  clinical  efﬁcacy  in
uch  patients.  One  of  the  strong  messages  conveyed  by  this
ore  modern  idea  of  thromboembolic  disease  is  that  some
atients  with  extensive  iliofemoral  venous  thrombosis  have
o  be  referred  to  a  vascular  surgeon  or  an  interventional
adiologist  for  a  consultation  in  order  for  the  long-term  ben-
ﬁts  of  early  treatment  with  endovascular  thrombolysis  to
e  assessed  [30].
he ‘‘open vein’’ concept
he  open  vein  concept  is  closely  connected  with  an  active
trategy,  the  aim  of  which  is  to  quickly  remove  the  occlusive
hrombus  (through  lysis  or  extraction).  The  result  of  this  is
hat  there  is  a  reduction  in  the  incidence  rate  of  recurrence
nd  PTS,  by  creating  permeability  and  by  keeping  greater
alve  integrity.  After  a  DVT  attack,  ‘‘natural’’  recanalisa-
ion  occurs  by  way  of  spontaneous  ﬁbrinolysis;  6  months
fter  a  deep  vein  occlusion  has  been  treated,  there  is  a  60%
t
i
a
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hance  that  the  segment  will  be  totally  reopened,  and  a  40%
hance  that  it  will  be  blocked  or  partially  recanalised,  and
 50%  chance  of  valve  insufﬁciency  [31]. Six  months  after
 DVT  incident,  Johnson  et  al.  observe  that  there  is  both
bstruction  and  reﬂux  in  65%  of  cases.  These  two  conditions
ccurring  together  is  a serious  concern,  which  multiplies  the
isk  of  a  PTS  by  3.5.  The  recanalisation  rate  depends  on  the
ocation.  It  is  much  lower  for  iliofemoral  thromboses  than
or  popliteal  or  distal  thromboses  [32]. It  would  appear  that
onventional  solutions  are  not  perfectly  suited  to  restor-
ng  permeability  and  valve  function  in  patients  who  have
uffered  an  acute  attack  of  DVT.  This  gives  strength  to  the
ntuitive  principle  that  it  is  beneﬁcial  to  facilitate  and  speed
p  recourse  to  lysis.  Arguments  that  back  up  the  ‘‘open
ein’’  concept  may  now  be  found  in  studies  on  patients  with
VT  who  were  treated  with  anticoagulants  alone.  Prandoni
t  al.  [33]  show  in  patients  who  develop  PTS  after  DVT,  that
he  frequency  of  residual  venous  thrombosis  or  popliteal
alve  reﬂux  is  much  higher  after  6  months  (47%  versus  23%).
oreover,  a  randomised  study  comparing  surgical  thrombec-
omy  with  anticoagulation  treatment,  conﬁrmed  that  there
as  greater  venous  permeability  and  a  reduction  in  PTS  with
he  ‘‘aggressive’’  option  than  with  anticoagulation  treat-
ent  alone  [34]. This  open  vein  hypothesis  is  also  borne  out
y  older  trials  with  systemic  thrombolysis:  in  the  Cochrane
roup  analysis  of  12  randomised  trials  systemic  thromboly-
is  versus  anticoagulation,  rate  post-thrombotic  syndrome
as  found  signiﬁcantly  lower  in  patients  in  the  ﬁrst  group
with  a  relative  risk  of  0.66).  Similarly,  studies  reporting  the
esults  of  the  thrombolysis  in  situ  are  in  line  of  this  concept:
he  national  venous  registry  determined  that  the  degree  of
ysis  was  achieved  predictive  permeability  to  1  year  (79%  for
rade  III  or  complete  lysis,  obtained  in  31%,  58%  for  grade  II
r  partial  lysis  50—90%,  obtained  in  58%  and  32%  for  grade
)  as  well  as  the  overall  rate  of  valvular  reﬂux  was  58%,  it
as  28%  for  patients  with  initial  complete  lysis  was  achieved
35].
Animal  experiments,  the  natural  history,  and  obser-
ational  and  randomised  studies,  have  shown  that  the
hrombus  can  be  destroyed,  permeability  restored,  and
alve  competence  maintained.  The  crucial  question  is:  can
his  be  achieved  without  major  risk,  and  is  there  also  a  real
linical  difference  in  the  long-term?  In  other  words,  is  the
isk/beneﬁt  analysis  favourable?
‘Modern’’ thrombolysis
n situ thrombolysis
he  principle  is  to  infuse  a  thrombolytic  agent  alone,  in
itu,  in  contact  with  the  thrombus,  via  a  closed-end,  multi-
ole  catheter,  over  a  great  length,  inserted  percutaneously
Cragg-MacNamara  type  catheter).  The  theoretical  beneﬁt
s  ﬁrstly  improved  efﬁcacy,  thanks  to  the  high  concentration
f  medication  being  injected  directly  into  the  thrombus,  and
econdly,  its  safety,  thanks  to  the  reduced  ﬁbrinogenolytic
ystemic  effects,  which  consequently  potentially  reduces
he  risk  of  haemorrhage.  The  molecule  currently  being  used
n  most  of  contemporary  studies  is  the  plasminogen  tissue
ctivator,  or  rtPa  (Actilyse®);  Urokinase,  withdrawn  from
he  American  market  for  a  long  time,  is  of  rare  use,  while
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in  France  it  has  a  marketing  authorization  for  treatment
with  intravenous  high  dose  (4000  to  5000  IU/kg  per  hour)
for  venous  occlusions  caused  by  thrombus  being  formed  or
recently  formed.
Based  on  thorough  documentation  of  the  scientiﬁc  litera-
ture  (19  trials,  with  quite  similar  designs),  dedicated  to  this
technique,  the  ACCP  2008  recommendations  were  drawn
up.  Signiﬁcant  lysis  was  reported  in  79%  of  945  patients
treated  using  this  method.  Older  trials,  and  in  particular
the  prospective,  multi-centre  National  Deep  Venous  Registry
[35], used  high  doses  of  Urokinase.  Of  those  287  patients
treated  in  65  centres,  serious  cases  of  haemorrhage  were
observed  in  almost  10%  of  cases,  most  of  which  were  located
near  the  puncture  point.  In  16%  of  cases,  the  haemorrhag-
ing  was  minor,  and  in  0.4%  cerebrovascular  accidents  (CVA)
were  reported.  More  recent  trials  (after  2000),  using  low
dose  infusions  of  rtpA  (0.5  to  1  mg/H)  reported  a  low  rate  of
major  local  haemorrhage  in  about  5%  of  patients  (no  CVA),
amounting  to  a  reduction  of  around  50%  compared  with  the
ﬁgures  for  thrombolysis  in  the  1990s  [36]. This  increased
level  of  safety  is  in  part  connected  with  a  likely  improvement
in  the  way  indications  were  chosen,  with  an  optimisation
of  the  required  dose,  but  it  is  even  more  likely  it  was
connected  with  the  use  of  a  percutaneous  micropuncture
needle  (21G  needle),  inserted  popliteally,  under  ultrasound
c
d
‘
bn into the common femoral vein in the same patient (b). Results
uidance,  in  a  patient  placed  in  a  decubitus  ventral  position
37]  (Fig.  4).
The  results  after  24  months  of  a  randomised  Norwegian
tudy,  which  started  in  2006  (CaVenT  study)  have  just  been
ublished  [38]. This  aim  of  this  study  was  to  compare  tradi-
ional  treatment  (LMWH  and  AVK)  with  in  situ  thrombolysis,
sing  rtpA  at  a  dose  of  00.1  mg/kg/h,  up  to  a  maximum  of
0  mg/24  h,  combined  with  LMWH,  without  a  vena  cava  ﬁl-
er,  followed  by  angioplasty  of  any  underlying  lesions  (at  the
iscretion  of  the  surgeon).  At  24  months,  34  patients  in  the
hrombolysis  group  (41%  of  the  total  108  subjects)  reached
he  primary  endpoint  of  SPT  versus  55  (56%  of  101  control
ubjects),  a  reduction  in  absolute  risk  of  developing  PTSD  by
5%,  associated  better  patency  of  the  iliac  vein  (65%  against
5%).  The  duration  of  thrombolytic  therapy  was  2/3  days
ith  88%  lysis  (total  or  between  50  and  90%),  the  price  of  9%
f  bleeding  complications  (3%  severe).
So,  despite,  undeniable  progress  in  terms  of  the
isk/beneﬁt  ratio,  the  technique  has  still  not  achieved  very
idespread  use,  mainly  because  it  is  time-consuming;  infu-
ion  time,  although  shorter  thanks  to  modern  protocols,
an  be  as  high  as  48  hours.  To  try  to  get  around  this  major
isadvantage,  thrombolytic  treatments  are  tending  towards
‘facilitated’’  thrombolysis  or  pharmacomechanical  throm-
olysis.
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Pharmacomechanical thrombolysis (PhMT)
There  are  two  ideas  for  carrying  out  this  interventional  ges-
ture,  which,  it  must  be  remembered,  has  been  attributed
a  grade  2C  recommendation  by  the  ACPP  2008,  and  should
be  used  in  preference  to  in  situ  thrombolysis  (but  always
used  in  association  with  it):  ﬁrst  generation  methods  com-
bining  percutaneous  thrombectomy  tools  and  traditional
in  situ  thrombolysis  infused  locally,  reduce  the  dose  and
the  ﬁbrinolytic  treatment  by  around  50%,  the  main  aim
of  which  is  to  improve  safety;  while  more  recent  methods
referred  to  as  ‘‘one-shot’’  methods  aim  to  quickly  disperse
an  intrathrombic  bolus  thrombolytic  to  ease  full  extraction
of  the  thrombus  in  one  short  procedure  lasting  between  1
and  3  hours,  thereby  avoiding  the  need  for  a  long  secondary
infusion.  There  are  three  types  of  tool  available,  which  are
generally  inserted  through  the  skin  into  the  popliteal  area
[7,21,39,40—46]:
• rotating  motorised  systems  that  break  up  the  thrombus
using  a  helix  (or  a  cage)  revolving  at  high  speed  (Amplatz
thrombectomy  Device;  Microvena,  Arrow-Terotola  per-
cutaneous  thrombolytic  Device;  Arrow,  Cragg-Castaneda
thrombolytic  brush;  Micro  Therapeutics)  or  which  dis-
integrate  the  thrombus  with  a  sinusoidal  Nitinol  wire
rotating  at  high  speed  (1,500  revs  per  minute)  between
two  occlusion  balloons,  15  to  30  cm  apart,  in  a  zone  where
the  rtPa  is  injected  (Trellis  system;  Bacchus  vascular).
The  Trellis  system  (Fig.  5)  is  activated  for  periods  of
15  minutes,  interspersed  with  infusions  of  5  to  10  mg  of
rtpA  (1  mg/minute  and  up  to  10  mg)  followed  by  manual
thromboaspiration  using  a  Desilet  or  a  traditional  wide-
cup  catheter  (10  F),  and  an  auto-expanding  stent  is  also
inserted  if  any  underlying  anomalies  are  discovered.  An
optional  vena  cava  ﬁlter  is  not  systematically  inserted
(indicated  in  cases  of  pulmonary  embolism  or  exten-
sion  associated  cava),  and  is  removed  after  3  months,
and  it  is  also  advisable  to  apply  intermittent  pneumatic
compression  for  24  hours.  The  Galway  Trellis  Experience,
reported  by  O’Sullivan,  in  36  patients  presenting  with
acute  DVT,  reported  100%  technical  success,  effectiveness
achieved  in  less  than  2  hours,  and  primary  permeability
Figure 5. Trellis system (Bacchus Vascular).
From [50].
Figure 6. AngioJet system (Possis).
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after  3  months  of  85%.  No  haemorrhaging  was  observed  in
his  experience  [43];
in addition  to  the  rotating  tools,  so-called  ‘‘rheolytic’’
instruments  can  also  be  used  (AngioJet;  Possis;  Hydroliser;
Cordis,  Oasis  Thrombectomy  System;  Boston  Scientiﬁc):
the  thrombus  is  initially  sprayed  with  ﬁbrinolytic  agent,
and  then  very  high  speed  jets  (400  km/h)  of  saline  are
applied,  thereby  creating  a  depression  by  way  of  a  Ven-
turi  effect,  so  that  the  fragmented  thrombotic  material
can  be  aspirated  (Fig.  6).  The  device  did  not  come  into
contact  with  the  wall,  but  there  was  a  theoretical  risk  of
haemolysis.  The  results  of  160  patients  from  the  PEARL
register  [44]  showed  that  lysis  was  achieved  in  93%  of  the
segments  treated,  achieved  in  almost  100%  of  cases  in
under  48  hours,  and  in  two  thirds  of  the  cases,  in  under
6  hours.  Two  relatively  recent,  non-randomised,  retro-
spective  cohorts  compared  the  TPM  with  the  AngioJet
system  and  the  traditional  technique:  the  ﬁrst  study  [18]
observed  that  there  was  no  difference  in  terms  of  the
lysis  rate  achieved,  but  much  quicker  success  with  the
AngioJet  (76  minutes/18  hours).  The  second  one  [17]  con-
ﬁrmed  this  clear  reduction  in  interventional  gesture  time
(26  hours/43  hours)  and  the  quantity  of  Urokinase  injected
(2.7  million  IU/5.6  millions  IU);
ﬁnally,  a  third  type  of  tool  is  available,  the  concept
of  which  is  based  on  boosting  the  effectiveness  of  the
thrombolytic  drug  with  ultrasound  (Ekos  EndoWave;  Ekos
Corporation,  Omniwave;  OmniSonics  Corp);  it  comes  in
the  form  of  a  triple  lumen  catheter  with  multiple  ultra-
sonic  transducers  which  emit  high  frequency,  low  energy
ultrasound  which  destroy  the  strands  of  ﬁbrin  of  the
thrombus,  thereby  helping  to  expose  the  plasminogen
receptors  to  the  locally-injected  ﬁbrinolytic  drug  [45].
There  is  no  mechanical  effect  unlike  the  other  systems,
but  the  infusion  time  will  probably  be  longer.  The  ﬁbri-
nolytic  drug  used  in  the  rare  studies  available  is  rtpA  at
a  dose  of  2  mg/H  for  5  hours,  then  1  mg/H  up  to  a  maxi-
mum  of  20  mg.  In  the  published  studies,  the  interventional
gesture  is  faster:  22  hours  compared  with  34  hours  for  tra-
ditional  thrombolysis  with  full  lysis  of  around  70%  and
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a  low  haemorrhagic  complication  rate  of  3.8%,  which  is
probably  thanks  to  the  lower  infusion  time  [46].
It should  be  remembered  that  treating  an  associated
anatomical  lesion  by  way  of  angioplasty-stenting  is  a  grade
2C  recommendation.  This  situation  is  not  rare,  especially
if  there  is  left  iliofemoral  DVT  in  a  young  patient  suffer-
ing  from  Cockett’s  syndrome,  in  the  form  of  stenosis  which
is  often  underestimated  by  the  venogram,  and  which  is
caused  by  compression  due  to  the  pulsating  of  the  right
iliac  artery;  the  proportion  of  patients  who  beneﬁt  from  this
extrasupport  in  the  published  series,  during  thrombolysis
gestures,  alone  or  facilitated,  is  between  33  and  67%  (56%).
Stents  are  used  almost  systematically  to  counter  the  spring-
back  often  observed  when  the  balloon  is  inﬂated;  Stents
used  are  auto-expanding  steel  models,  or  more  recently
models  in  Nitinol.  A  recent  meta-analysis  on  the  use  of  var-
ious  mechanical  percutaneous  thrombectomy  systems  was
reported  [47]  in  the  form  of  16  retrospective  series  using
rheolytic,  rotating  or  ultrasound  assisted  systems,  on  a
total  of  481  patients.  It  should  be  pointed  out  that  there
are  no  randomised  studies  currently  available.  Technical
success  (grade  II  or  III  lysis)  was  observed  in  between  83
and  100%  of  patients,  and  the  overall  incidence  rate  for
haemorrhagic  complications  requiring  a  transfusion  came  to
7.5%.
The  Attract  study  [48], sponsored  by  the  National  Heart
and  Blood  Institute  is  a  randomised,  double-blind  phase
III,  multi-centre  study  with  two  parallel  arms.  This  ran-
domised  trial  is  currently  being  carried  out  in  60  centres
throughout  North  America  on  692  patients  suffering  from
symptomatic  DVT.  The  patients  receive  either  pharma-
comechanical  treatment  combined  with  standard  treatment
(anticoagulant  and  elastic  compression)  or  the  standard  tra-
ditional  treatment.  Endovascular  techniques  use  either  rtpA
alone,  at  a  dose  of  00.1  mg/kg  per  hour,  up  to  a  maximum
of  24  hours  with  a  maximum  dose  of  35  mg,  or  rtpA  deliv-
ered  in  one-shot  via  a  trellis  system  or  an  AngioJet,  with  up
to  a  maximum  of  25  mg  administered.  The  statistical  power
of  this  study  was  weighted  in  order  to  ascertain  whether
using  pharmacomechanical  techniques  might  reduce  the
occurrence  of  a  PTS  by  a  third  after  2  years  of  follow-
up.
The  PTS  is  assessed  every  6  months  against  the  Vil-
lalta  scale,  and  to  date  over  100  patients  have  been
recruited  and  the  monthly  inclusion  rate  continues  to
climb.
The  results  after  6  months  of  a  randomised  study  (Tor-
pedo  study)  have  just  been  published  [49]. This  study  was
carried  out  in  symptomatic  patients  suffering  from  acute
proximal  DVT,  and  has  compared  anticoagulants  alone  (81
patients),  versus  pharmacomechanical  treatment:  a  combi-
nation  of  mechanical  thrombectomy,  angioplasty,  stenting
and  rtpA  (88  patients).  Although  this  study  did  not  use  a  val-
idated  measurement  (such  as  the  Villalta  score)  to  deﬁne
whether  and  to  what  extent  the  patient  was  suffering  from
PTS,  it  nonetheless  revealed  a  signiﬁcant  reduction  in  the
incidence  of  cases  of  weak  or  moderate  post-thrombotic
syndrome  after  6  months,  when  compared  with  the  tradi-
tional  treatment  (4%/25%),  without  an  increase  in  the  risk
of  haemorrhaging,  estimated  to  be  2%.
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iven  that  the  clinical  and  biological  phenotypes  within  the
opulation  presenting  with  DVT  vary  widely,  it  is  essential
or  clinical  decisions  to  be  guided  by  thorough  randomised
tudies.  If  they  are  currently  underway,  or  not  yet  available,
linical  common  sense  justiﬁes  these  treatments  being  pre-
cribed  for  those  who  are  likely  to  beneﬁt,  with  as  low  a  risk
s  possible.
A  number  of  factors  may  reasonably  inﬂuence  such  deci-
ions:
an  assessment  of  the  risk  of  bleeding:  this  risk  must  be
assessed  by  taking  into  account  recent  major  surgery,
trauma,  pregnancy,  cardiorespiratory  arrest,  other  inva-
sive  procedures,  lesions  to  the  central  nervous  system,
digestive  system,  or  renal  failure;
the  clinical  severity  of  the  deep  vein  thrombosis:  urgent
endovascular  thrombolysis  is  indicated  to  save  a  limb,  or
in  the  case  of  other  serious  complications  such  as  Phleg-
matia  Caerulea  Dolens  or  extensive  thrombosis  of  the
vena  cava,  in  particular  if  a  suprarenal  extension  is  in
place  —  that  might  lead  to  a  fatal  pulmonary  embolism
or  acute  renal  failure.  The  use  of  in  situ  thrombolysis  in
such  situations  is  justiﬁed  if  there  is  no  other  effective
treatment  available.  In  other  situations,  it  is  advisable  to
use  this  measure,  as  non-urgent  treatment,  after  strictly
assessing  the  beneﬁts  in  relation  to  the  risks.  In  such
cases,  a  lower  threshold  must  be  applied  to  exclude
patients  who  would  be  at  a  greater  risk  of  haemorrhaging
if  they  underwent  thrombolytic  treatment;
anatomical  extension  of  deep  vein  thrombosis:  patients
with  iliofemoral  DVT  have  a  greater  risk  of  both  PTS  and
thrombotic  relapse.  Although  current  studies  entail  some
methodological  limitations,  it  seems  that  these  patients
might  beneﬁt  from  endovascular  treatment.  For  those
patients  who  have  a  low  risk  of  bleeding,  a  compromise
between  the  risk  and  the  possible  beneﬁts  of  non-urgent,
ﬁrst-line  treatment  should  be  discussed.  Because  of  a
lack  of  actual  proof,  a  very  low  decision  threshold  should
be  applied  in  order  to  exclude  patients  if  there  is  the
slightest  risk  of  bleeding.  Patients  with  asymptomatic  DVT
and  venous  thrombosis  of  the  legs  should  not  be  treated
with  thrombolysis,  mainly  because  the  risk  of  PTS  is  low.
Finally,  patients  with  chronic  femoropopliteal  thrombosis
should  not  be  given  this  type  of  treatment;
assessment  of  life  expectancy,  functional  status  and
comorbidity:  patients  who  are  chronically  unable  to  walk,
or  who  have  a  low  life  expectancy  are  unlikely  to  beneﬁt
from  this  type  of  treatment.  However,  young  patients,
who  presumably  have  a  low  risk  of  bleeding  are  more
suitable  to  receive  this  type  of  treatment;
patient  preference:  the  beneﬁt-risk  should  be  clearly
explained  to  the  patient  to  guide  their  choice.
A  treatment  algorithm  of  acute  iliofemoral  DVT,  put  for-
ard  by  O’Sullivan  [50], is  shown  in  Fig.  7.  Its  adaptation
o  French  patients  faces  for  the  moment  the  rule  of  Afss-
ps  recommendations,  lack  of  marketing  authorizations  for
ctilyse  (recall  that  the  WMA  has  Urokinase,  systemically  in
ST  acute),  the  major  extracost  induced  by  the  use  of  power
ools  or  rotational  rhéolytiques  (which  also  are  not  all  dis-
ributed  in  our  country,  and  whose  funding  is  not  supported).
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[igure 7. Treatment algorithm for deep vein thrombosis put for-
ard by O’Sullivan [50].
onclusion
n  increasing  number  of  arguments  put  forward  by  proof-
ased  medicine  give  weight  to  the  validity  of  open  vein
heory  for  the  prevention  of  the  post-thrombotic  syndrome
fter  iliofemoral  deep  vein  thrombosis.  It  has  been  estab-
ished  that  modern,  pharmacomechanical  methods  have  a
isk/beneﬁt  ratio  that  appears  to  be  positive  for  this  pre-
ise  sub-group,  to  whom  honest  information  should  be  given
n  alternative  treatments.
isclosure of interest
he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.
eferences
[1] Recommandations de bonne pratique : prévention et traite-
ment de la maladie thromboembolique en médecine. Agence
franc¸aise de sécurité sanitaire des produits de santé, décembre
2009.
[2] Watson LI, Armon MP. Thrombolysis for acute deep vein throm-
bosis. Cochrane Database Syst Rev 2004;(4):CD002783.
[3] Meissner AJ, Misiak A, Ziemski JM, Scharf R, Rudowski W,
Huszcza S, et al. Hazards of thrombolytic therapy in deep vein
thrombosis. Br J Surg 1987;74:991—3.
[4] Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE,
Comerota AJ. Antithrombotic therapy for venous thromboem-
bolic disease: American college of chest physicians evidence
based clinical practice guidelines (8th ed.). Chest 2008;133(6
Suppl.):454S—545S.
[5] Elsharawy M, Elzayat E. Early results of thrombolysis vs anti-
coagulation in iliofemoral venous thrombosis: a randomized
clinical study. Eur J Vasc Endovasc Surg 2002;24:209—14.
[6] Bjarnason H, Kruse JR, Asinger DA, Nazarian GK, Dietz Jr
CA, Caldwell MD, et al. Iliofemoral deep venous thrombosis:
safety and efﬁcacy outcome during 5 years of catheter-
directed thrombolytic therapy. J Vasc Interv Radiol 1997;8:
405—18.
[J.-M.  Pernès  et  al.
[7] Comerota AJ, Kagan SA. Catheter-directed thrombolysis for
the treatment of acute iliofemoral deep venous thrombosis.
Phlebology 2000;15:149—55.
[8] Laiho MK, Oinonen A, Sugano N, Harjola VP, Lehtola AL,
Roth WD, et al. Preservation of venous valve function after
catheter-directed and systemic thrombolysis for deep venous
thrombosis. Eur J Vasc Endovasc Surg 2004;28:391—689.
[9] AbuRahma AF, Perkins SE, Wulu JT, Ng HK. Iliofemoral deep
vein thrombosis: conventional therapy versus lysis and per-
cutaneous transluminal angioplasty and stenting. Ann Surg
2001;233:752—60.
10] Castaneda F, Li R, Young K, Swischuk JL, Smouse B, Brady
T. Catheter-directed thrombolysis in deep venous thrombosis
with use of reteplase: immediate results and complications
from a pilot study. J Vasc Interv Radiol 2002;13:577—80.
11] Grunwald MR, Hofmann LV. Comparison of Urokinase, alteplase,
and reteplase for catheter-directed thrombolysis of deep
venous thrombosis. J Vasc Interv Radiol 2005;15:347—52.
12] Horne 3rd MK, Mayo DJ, Cannon 3rd RO, Chen CC, Shawker TH,
Chang R. Intraclot recombinant tissue plasminogen activator
in the treatment of deep venous thrombosis of the lower and
upper extremities. Am J Med 2000;108:251—5.
13] Jackson LS, Wang XJ, Dudrick SJ, Gersten GD. Catheter-
directed thrombolysis and/or thrombectomy with selective
endovascular stenting as alternatives to systemic anticoagu-
lation for treatment of acute deep vein thrombosis. Am J Surg
2005;190:864—8.
14] Kasirajan K, Gray B, Ouriel K. Percutaneous AngioJet thrombec-
tomy in the management of extensive deep venous thrombosis.
J Vasc Interv Radiol 2001;12:179—85.
15] Lin PH, Zhou W,  Dardik A, Mussa F, Kougias P, Hedayati
N, et al. Catheter-direct thrombolysis versus pharmacome-
chanical thrombectomy for treatment of symptomatic lower
extremity deep venous thrombosis. Am J Surg 2006;192:782—8.
16] Kim HS, Patra A, Paxton BE, Khan J, Streiff MB. Adjunctive
percutaneous mechanical thrombectomy for lower extremity
deep vein thrombosis: clinical and economic outcomes. J Vasc
Interv Radiol 2006;17:1099—104.
17] Ogawa T, Hoshino S, Midorikawa H, Sato K. Intermittent pneu-
matic compression of the foot and calf improves the outcome
of catheter-directed thrombolysis using low dose Urokinase in
patients with acute proximal venous thrombosis of the leg. J
Vasc Surg 2005;42:940—94.
18] Semba CP, Dake MD. Iliofemoral deep venous thrombosis:
aggressive therapy with catheter-directed thrombolysis. Radi-
ology 1994;191:487—94.
19] Semba CP, Dake MD. Catheter-directed thrombolysis for
iliofemoral venous thrombosis. Semin Vasc Surg 1996;9:
26—33.
20] Sillesen H, Just S, Jorgensen M, Baekgaard N. Catheter-
directed thrombolysis for treatment of iliofemoral deep venous
thrombosis is durable, preserves venous valve function and may
prevent chronic venous insufﬁciency. Eur J Vasc Endovasc Surg
2005;30:556—62.
21] Vedantham S, Vesely TM, Parti N, Darcy M, Hovsepian
DM, Picus D. Lower extremity venous thrombolysis with
adjunctive mechanical thrombectomy. J Vasc Interv Radiol
2002;13:1001—8.
22] Verhaeghe R, Stockx L, Lacroix H, Vermylen J, Baert AL.
Catheter-directed lysis of iliofemoral vein thrombosis with use
of rtPA. Eur Radiol 1997;7:996—1001.
23] Henke PK, Comerota A J. An update on etiology, preven-
tion, and therapy of post-thrombotic syndrome. J Vasc Surg
2011;53:500—9.24] Henke PK, Wakeﬁeld T. Thrombus resolution and vein wall
injury: dependence on chemokines and leukocytes. Thromb Res
2009;123(Suppl. 4):S72—8.
[[
[
[
[
[
[
[
[
[
[
[Acute  deep  vein  thrombosis  and  endovascular  techniques  
[25] Kahn SR, Ginsberg JS. The post-thrombotic syndrome: current
knowledge, controversies, and directions for future research.
Blood Rev 2002;16:155—65.
[26] Tick LW, Kramer MH, Rosendaal FR, Faber WR. Risk factors for
post-thrombotic syndrome in patients with a ﬁrst deep venous
thrombosis. J Thromb Haemost 2008;12:2075—81.
[27] Villalta S, Bagatella P, Piccioli A, Lensing G, Prins M, Prandoni P.
Assessment of validity and reproducibility of a clinical scale for
the post-thrombotic syndrome. Haemostasis 1994;24:158—68.
[28] Kahn SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron MJ,
et al. Determinants and time course of the post-thrombotic
syndrome after acute deep venous thrombosis. Ann Intern Med
2008;149:698—707.
[29] Ofﬁce of the surgeon general. Resources on deep venous throm-
bosis and pulmonary embolism. Available at: http://www.
surgeongeneral.gov/topics/deepvein/calltoaction/resources.
html. Accessed November 10, 2010.
[30] Pollack CV. Advanced management of acute iliofemoral deep
venous thrombosis: emergency department and beyond. Ann
Emerg Med 2011;57(4):590—9.
[31] Roumen-Klappe EM, Janssen MC, van Rossum J, Holewijn S, Van
Bokhoven MM, Kaasjager K, et al. Inﬂammation in deep vein
thrombosis and the development of the post-thrombotic syn-
drome: a prospective study. J Thromb Haemost 2009;7:582—7.
[32] Johnson BF, Manzo RA, Bergelin RO, Strandness DE. Relationship
between changes in the deep venous system and the develop-
ment of the post-thrombotic syndrome after an acute episode
of lower limb deep vein thrombosis: a one to six years follow-
up. J Vasc Surg 1995;2:307—12.
[33] Prandoni P, Lensing AW, Prins MH, Frulla M, Marchiori A,
Bernardi E, et al. Below-knee elastic compression stockings
to prevent the post-thrombotic syndrome: a randomized, con-
trolled study. Ann Intern Med 2004;141:249—56.
[34] Plate G, Eklöf B, Norgren L, Ohlin P, Dahlström JA. Venous
thrombectomy for iliofemoral vein thrombosis: 10-year results
of a prospective randomised study. Eur J Vasc Endovasc Surg
1997;14:367—74.
[35] Mewissen MW, Seabrook GR, Meissner MH, Cynamon J,
Labropoulos N, Haughton SH. Catheter-directed thromboly-
sis for lower extremity deep venous thrombosis: report of a
national multicenter registry. Radiology 1999;211:39—49.
[36] Grunwald MR, Hofmann LV. Comparison of urokinase, alteplase,
and reteplase for catheter-directed thrombolysis of deep
venous thrombosis. J Vasc Interv Radiol 2004;15:347—52.
[37] Vedantham S, Millward SF, Cardella JF, Hofmann LV, Razavi MK,
Grassi CJ, et al. Society of interventional radiology position
statement: treatment of acute iliofemoral deep venous throm-
bosis with use of adjunctive catheter-directed intrathrombus
thrombolysis. J Vasc Interv Radiol 2009;20(7 Suppl.):S332—5.
[733
38] Enden T, Kløw NE, Sandvik L, Slagsvold CE, Ghanima W, Haf-
sahl G, et al. Catheter-directed thrombolysis vs. anticoagulant
therapy alone in deep venous thrombosis: results of an open
randomized, controlled trial reporting on short-term patency.
J Thromb Haemost 2009;7:1268—75.
39] Lee KH, Han H, Lee KJ, Yoon CS, Kim SH, Won JY, et al. Mechani-
cal thrombectomy of acute iliofemoral deep venous thrombosis
with use of an arrow-trerotola percutaneous thrombectomy
device. J Vasc Interv Radiol 2006;17:487—95.
40] Kasirajan K, Gray B, Ouriel K. Percutaneous AngioJet thrombec-
tomy in the management of extensive deep venous thrombosis.
J Vasc Interv Radiol 2001;12(2):179—85.
41] Gasparis AP, Labropoulos N, Tassiopoulos AK, Phillips B, Pagan J,
Cheng L, et al. Mid-term follow-up after pharmacomechanical
thrombolysis for lower extremity deep venous thrombosis. Vasc
Endovascular Surg 2009;43(1):61—8.
42] Arko FR, Davis 3rd CM, Murphy EH, Smith ST, Timaran
CH, Modrall JG, et al. Aggressive percutaneous mechani-
cal thrombectomy of deep venous thrombosis: early clinical
results. Arch Surg 2007;142:513—8.
43] O’Sullivan GJ, Lohan DG, Gough N, Cronin CG, Kee ST. Phar-
macomechanical thrombectomy of acute deep vein thrombosis
with the Trellis-8 isolated thrombolysis catheter. J Vasc Interv
Radiol 2007;18:715—7.
44] Lookstein R. PEARL registry mid-term analysis. Paper presented
at: ISET 2009; Florida, United States.
45] Francis CW, Blinc A, Lee S, Cox C. Ultrasound accelerates trans-
port of recombinant tissue plasminogen activator into clots.
Ultrasound Med Biol 1995;21(3):419—24.
46] Parikh S, Motarjeme A, McNamara T, Raabe R, Hagspiel K,
Benenati JF, et al. Ultrasound accelerated thrombolysis for the
treatment of deep venous thrombosis: initial clinical experi-
ence. J Vasc Interv Radiol 2008;19:521—8.
47] Karthikesalingam A, Young EL, Hinchliffe RJ, Loftus IM,
Thompson MM, Holt PJE. A systematic review of percuta-
neous mechanical thrombectomy in the treatment of deep
venous thrombosis. Eur J Vasc Endovasc Surg 2011;41(4):
554—65.
48] Acute venous thrombosis: thrombus removal with adjunc-
tive catheter-directed thrombolysis (ATTRACT). December
4, 2009. Available at: http://clinicaltrials.gov/ct2/show/
NCT00790335?term ATTRACT&rank 2. Accessed December 22,
2009.
49] Shariﬁ M, Mehdipour M, Bay C, Smith G, Shariﬁ J. Endove-
nous therapy for deep venous thrombosis: the TORPEDO trial.
Catheter Cardiovasc Interv 2010;76(3):316—25.
50] O’Sullivan GJ. The role of interventional radiology in the
management of deep venous thrombosis: advanced therapy.
Cardiovasc Intervent Radiol 2011;34(3):445—61.
